Attitudes toward preimplantation genetic testing and quality of life among individuals with hereditary diffuse gastric cancer syndrome

Ibrahim H Shah; Erin E Salo-Mullen; Kimberly A Amoroso; David Kelsen; Zsofia K Stadler; Jada G Hamilton

doi:10.1186/s13053-022-00239-9

Attitudes toward preimplantation genetic testing and quality of life among individuals with hereditary diffuse gastric cancer syndrome

Hered Cancer Clin Pract. 2022 Sep 2;20(1):31. doi: 10.1186/s13053-022-00239-9.

Authors

Ibrahim H Shah¹, Erin E Salo-Mullen², Kimberly A Amoroso², David Kelsen^{2

3}, Zsofia K Stadler^{2

3}, Jada G Hamilton^{4

5

6}

Affiliations

¹ Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA.
⁴ Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hamiltoj@mskcc.org.
⁵ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hamiltoj@mskcc.org.
⁶ Department of Psychiatry, Weill Cornell Medical College, Cornell University, New York, NY, USA. hamiltoj@mskcc.org.

Abstract

Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is an autosomal dominant hereditary cancer predisposition associated with germline pathogenic/likely pathogenic variants in the CDH1 gene. Identifying early stage HDGC is difficult, and prophylactic measures can be effective in preventing incidence. Preimplantation Genetic Testing (PGT) can provide information about CDH1 variant status, HDGC risk, and limit familial transmission of CDH1 variants. To date, however, little is known about the attitudes of individuals with CDH1 variants towards PGT.

Methods: Given that little is known about the reproductive attitudes of individuals with HDGC, we recruited participants with CDH1 variants from a familial gastric cancer registry and administered a cross-sectional survey with open- and closed-ended response items. We assessed attitudes regarding PGT and the effect of HDGC on quality of life.

Results: Participants (n = 21) were predominantly partnered (61.9%), had a personal cancer history (71.4%), and had biological children (71.4%). Interest in learning about PGT was high; 66.7% of participants were interested in PGT and 90.5% approved of healthcare providers discussing PGT with individuals with CDH1 variants. Attitudes regarding personal use were varied. Among all participants, 35% would not, 25% were uncertain, and 40% would use PGT. Personal philosophy and preferences for family and reproduction were key factors related to PGT attitudes. HDGC had moderate effects on participants' quality of life, including social relationships, health behaviors, and emotional experiences including worry about cancer risk and guilt regarding familial implications.

Conclusion: PGT was identified by participants as acceptable for use in a variety of contexts and benefits of reproductive counseling involving PGT may extend beyond CDH1 carriers to family members' reproductive behaviors. Dispositions towards PGT are governed by personal philosophy or belief systems. These findings can help guide providers counseling individuals with CDH1 variants.

Keywords: Cancer; Inherited cancer syndrome; Preimplantation genetic testing; Reproduction; Risk.

Abstract

Grants and funding